#hereditary-angioedema

Intellia's Gene Editing Breakthrough: A New Era

Intellia Therapeutics has achieved a historic milestone in gene editing with positive Phase 3 results for hereditary angioedema. This groundbreaking development holds transformative potential for the biotech industry and patients worldwide. Discover the implications and future prospects of this innovation.